Meeder Asset Management Inc. Makes New $41,000 Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,051 shares of the biopharmaceutical company’s stock, valued at approximately $41,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its position in Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after buying an additional 1,312,934 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Emergent BioSolutions during the 4th quarter worth $58,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Emergent BioSolutions in the fourth quarter worth $232,000. Oxford Asset Management LLP acquired a new position in Emergent BioSolutions in the fourth quarter valued at about $67,000. Finally, Los Angeles Capital Management LLC increased its stake in Emergent BioSolutions by 20.1% in the first quarter. Los Angeles Capital Management LLC now owns 193,991 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 32,460 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Stock Up 3.1 %

Shares of NYSE:EBS opened at $7.87 on Monday. The business has a fifty day simple moving average of $9.68 and a 200 day simple moving average of $6.08. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The firm has a market cap of $416.40 million, a P/E ratio of -0.71 and a beta of 1.60. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The company had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same quarter last year, the business earned ($1.06) earnings per share. Analysts predict that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on EBS shares. Rodman & Renshaw restated a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday. Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research note on Friday, August 16th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.